Which types of breast cancer are more likely to have lung cancer?
In recent days, according to the latest data published by IARC, breast cancer is no longer the world ‘ s largest cancer, with an estimated 2.48 million new cases of lung cancer worldwide in 2022, more than 2.3 million breast cancer, regaining its name as the world ‘ s largest cancer and becoming the world ‘ s largest cancer killer with up to 1.82 million deaths. However, lung cancer continues to be a cause of concern for breast cancer patients, and research shows that the risk of second primary cancer among women increases slightly compared to the general population. Moreover, breast cancer patients are 1.25 times more likely than the general population to follow up with primary lung cancer. Today we’ll talk about which breast cancer patients are more likely to have lung cancer? In a mass-based, systematic evaluation and Meta analysis, scholars have found that the risk of primary lung cancer among women with breast cancer is slightly higher than in the general population, but the mechanisms for lung cancer among breast cancer patients are not yet clear and the increase in this risk may be linked to a number of factors. 1. There is a strong correlation between the mutation of genes and estrogen receptor (ER) expressions, which are the most important drivers of lung cancer. There has been a significant increase in the EGFR mutation of female lung cancer compared to male lung cancer. 2. The impact of the release of breast cancer patients has increased the risk of second-prevalence cancer, although it can reduce the rate of local re-emergence and mortality of breast cancer. Compared to women with untreated breast cancer, the risk of primary lung cancer increases over time. In particular, the risk of lung cancer among smokers who undergo treatment after diagnosis of breast cancer has increased significantly. 3. Estrogen affects women aged < 50 years who are diagnosed with breast cancer at a higher risk of lung cancer than those aged < 50 years, which may be associated with high levels of estrogen in the body and with high ER expression. High-level estrogens are a driver of lung cancer and can induce non-small cell lung cancer cell proliferation. Moreover, the incidence of second-prevalence lung cancer among ER-positive breast cancer patients who have been treated with ER for five years has decreased significantly compared to those who have been treated with MER for two years. As a result, high estrogens and ERs increase the risk of lung cancer among young breast cancer women, while suggesting that estrogen treatment plays an important role in reducing the risk of lung cancer and death. In the case of ER-positive breast cancer patients, endocrine treatment should be standardized to reduce the risk of primary lung cancer. Women with a genetic gene < 50 years of age diagnosed with breast cancer are more likely to be gene-related. When comparing single-capture breast cancers with those with second-prevalence cancers, it is found that, regardless of the age at which breast cancer is diagnosed, at least 7 per cent of those with second-prevalence cancers are found to have genetic mutations other than BRCA1/2, while those with < 30-year-old polygenic cancers have genetic mutations as high as 25 per cent. Thus, breast cancer patients with second primary cancer are subject to multi-genetic testing and genetic counselling regardless of their age and family history. Based on the above, the risk of second-prevalence lung cancer is higher among women diagnosed with breast cancer < 50 years of age. This high risk therefore underscores the importance of standardized treatment and close follow-up for young breast cancer patients.
